What is aBMD target price?
ABMD: Lowering target price to $352.00 ABIOMED INC has an Investment Rating of HOLD; a target price of $352.000000; an Industry Subrating of High; a Management Subrating of Medium; a Safety Subrating of Medium; a Financial Strength Subrating of Medium; a Growth Subrating of Medium; and a Value Subrating of Medium.
Should you hold Abiomed (aBMD) stock?
The consensus among Wall Street analysts is that investors should "hold" Abiomed stock. A hold rating indicates that analysts believe investors should maintain any existing positions they have in ABMD, but not buy additional shares or sell existing shares. View analyst ratings for Abiomed or view top-rated stocks.
What will Abiomed stock price reach in the next year?
Their predictions range from $215.00 to $400.00. On average, they expect ABIOMED's share price to reach $318.3333 in the next year. This suggests a possible upside of 67.0% from the stock's current price. View Analyst Price Targets for ABIOMED.
Who sold aBMD stock in the last quarter?
ABMD stock was sold by a variety of institutional investors in the last quarter, including Villere ST Denis J & Co. LLC, Crossmark Global Holdings Inc., State of Alaska Department of Revenue, Chicago Capital LLC, Retirement Systems of Alabama, Gulf International Bank UK Ltd, Nordea Investment Management AB, and Royal London Asset Management Ltd..
Is ABMD stock a buy?
Abiomed has received a consensus rating of Hold. The company's average rating score is 2.00, and is based on 1 buy rating, 2 hold ratings, and 1 sell rating.
Is Abiomed a public company?
Abiomed is a publicly-traded medical devices company that develops and manufactures external and implantable circulatory support devices.
What does Abiomed Inc do?
Abiomed (NASDAQ: ABMD) is a leading provider of groundbreaking medical technology that provides circulatory and oxygenation support. The Impella® heart pump platform is designed to enable the heart to rest and recover by improving blood flow and/or temporarily assisting with the pumping function of the heart.
What industry is Abiomed?
Abiomed Inc (Abiomed) is a medical device company that develops, manufactures and markets circulatory support devices. The devices replace or assist the pumping function in a failing heart.
Is Abiomed a Fortune 500 company?
Maker of the first artificial heart, Abiomed's revenues have been racing on sales of the Impella heart pump for patients with heart failure, a growing market....Growth Rates and Ranks.Revenue 3 Yr Growth Rank37Total Return 3 Yr Annual Rate79%Beat S&P 500 (9.6%)yesP/E Ratio664 more rows
When did Abiomed go public?
1987: Applied Biomedical is merged into newly formed Abiomed, which is taken public. 1994: The National Institutes of Health (NIH) selects company to receive funding for final stage of artificial heart development.
Who are Abiomed competitors?
Abiomed's top competitors include Dong-A ST, Gerresheimer, Fresenius Kabi and Sopharma. Abiomed is a company providing medical devices for circulatory support.
Why is Abmd down?
Shares of Abiomed (ABMD 2.25%) closed down 10% today after the medical-device maker reported earnings from its second fiscal quarter and muted guidance for the quarter ahead due to the COVID-19 pandemic.
Is Abiomed a good company to work for?
Is ABIOMED a good company to work for? ABIOMED has an overall rating of 3.5 out of 5, based on over 272 reviews left anonymously by employees. 58% of employees would recommend working at ABIOMED to a friend and 78% have a positive outlook for the business.
Who is the CEO of Abiomed?
Michael R. Minogue (Apr 6, 2004–)Abiomed / CEO
Who started Abiomed?
Abiomed (NSDQ:ABMD) founder and cardiovascular pioneer David Lederman last week died of pancreatic cancer at the age of 68.
Who invented impella?
Thorsten SiessThorsten Siess, Abiomed's Chief Technology Officer and Inventor of Impella® Shares his Insights on the Impella Platform of Heart Pumps.
When is Abiomed earnings call?
What does "hold" mean in ABMD?
How can I listen to Abiomed's earnings call? Abiomed will be holding an earnings conference call on Thursday, August 5th at 8:00 AM Eastern. Interested parties can register for or listen to the call using this link or dial in at 404-537-3406 with passcode "5929017".
How much does Abiomed make?
A hold rating indicates that analysts believe investors should maintain any existing positions they have in ABMD, but not buy additional shares or sell existing shares. View analyst ratings for Abiomed or view top-rated stocks.
Nasdaq Global Select
Abiomed has a market capitalization of $14.48 billion and generates $847.52 million in revenue each year. The medical equipment provider earns $225.52 million in net income (profit) each year or $4.94 on an earnings per share basis.
Environmental, Social, and Governance Rating
Abiomed is a provider of medical devices in circulatory support and offer a continuum of care in heart recovery to acute heart failure patients.
Business Summary
"B" score indicates good relative ESG performance and an above-average degree of transparency in reporting material ESG data publicly and privately. Scores range from AAA to D.
American Battery Technology Company Secures Additional 1,800 Acres of Lithium-Bearing Claims in Tonopah Flats Nevada
Abiomed is a provider of medical devices in circulatory support and offer a continuum of care in heart recovery to acute heart failure patients.
American Battery Technology Company CEO Ryan Melsert Invited to Speak at Bloomberg New Energy Finance Summit
Company to Stake Additional Claims Expanding Tonopah Flats Exploration ProjectReno, Nev., Feb.
